KR100864745B1 - 리네졸리드 결정 형태 ⅱ - Google Patents

리네졸리드 결정 형태 ⅱ Download PDF

Info

Publication number
KR100864745B1
KR100864745B1 KR1020077016678A KR20077016678A KR100864745B1 KR 100864745 B1 KR100864745 B1 KR 100864745B1 KR 1020077016678 A KR1020077016678 A KR 1020077016678A KR 20077016678 A KR20077016678 A KR 20077016678A KR 100864745 B1 KR100864745 B1 KR 100864745B1
Authority
KR
South Korea
Prior art keywords
solvent
methyl
phenyl
oxazolidinyl
morpholinyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020077016678A
Other languages
English (en)
Korean (ko)
Other versions
KR20070087178A (ko
Inventor
마이클 에스. 버그렌
Original Assignee
파마시아 앤드 업존 캄파니 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22658183&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR100864745(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 파마시아 앤드 업존 캄파니 엘엘씨 filed Critical 파마시아 앤드 업존 캄파니 엘엘씨
Publication of KR20070087178A publication Critical patent/KR20070087178A/ko
Application granted granted Critical
Publication of KR100864745B1 publication Critical patent/KR100864745B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/22—Oxygen atoms attached in position 2 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to other ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
KR1020077016678A 2000-02-02 2001-01-29 리네졸리드 결정 형태 ⅱ Expired - Fee Related KR100864745B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17983700P 2000-02-02 2000-02-02
US60/179,837 2000-02-02

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020027009923A Division KR100781815B1 (ko) 2000-02-02 2001-01-29 리네졸리드 결정 형태 ⅱ

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020087010742A Division KR20080044358A (ko) 2000-02-02 2001-01-29 리네졸리드 결정 형태 ⅱ

Publications (2)

Publication Number Publication Date
KR20070087178A KR20070087178A (ko) 2007-08-27
KR100864745B1 true KR100864745B1 (ko) 2008-10-22

Family

ID=22658183

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020077016678A Expired - Fee Related KR100864745B1 (ko) 2000-02-02 2001-01-29 리네졸리드 결정 형태 ⅱ
KR1020027009923A Expired - Fee Related KR100781815B1 (ko) 2000-02-02 2001-01-29 리네졸리드 결정 형태 ⅱ
KR1020087010742A Ceased KR20080044358A (ko) 2000-02-02 2001-01-29 리네졸리드 결정 형태 ⅱ

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020027009923A Expired - Fee Related KR100781815B1 (ko) 2000-02-02 2001-01-29 리네졸리드 결정 형태 ⅱ
KR1020087010742A Ceased KR20080044358A (ko) 2000-02-02 2001-01-29 리네졸리드 결정 형태 ⅱ

Country Status (30)

Country Link
EP (1) EP1255754B1 (cg-RX-API-DMAC7.html)
JP (1) JP5235256B2 (cg-RX-API-DMAC7.html)
KR (3) KR100864745B1 (cg-RX-API-DMAC7.html)
CN (1) CN1221547C (cg-RX-API-DMAC7.html)
AR (1) AR027261A1 (cg-RX-API-DMAC7.html)
AT (1) ATE297920T1 (cg-RX-API-DMAC7.html)
AU (1) AU782138B2 (cg-RX-API-DMAC7.html)
BR (1) BR0107667A (cg-RX-API-DMAC7.html)
CA (1) CA2395603C (cg-RX-API-DMAC7.html)
CO (1) CO5261555A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ302292B6 (cg-RX-API-DMAC7.html)
DE (1) DE60111497T2 (cg-RX-API-DMAC7.html)
DK (1) DK1255754T3 (cg-RX-API-DMAC7.html)
EA (1) EA004434B1 (cg-RX-API-DMAC7.html)
EE (1) EE05197B1 (cg-RX-API-DMAC7.html)
ES (1) ES2242728T3 (cg-RX-API-DMAC7.html)
HU (1) HUP0301076A3 (cg-RX-API-DMAC7.html)
IL (1) IL151010A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA02007471A (cg-RX-API-DMAC7.html)
MY (1) MY122829A (cg-RX-API-DMAC7.html)
NO (2) NO323459B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ520541A (cg-RX-API-DMAC7.html)
PE (1) PE20011086A1 (cg-RX-API-DMAC7.html)
PL (1) PL356433A1 (cg-RX-API-DMAC7.html)
PT (1) PT1255754E (cg-RX-API-DMAC7.html)
SI (1) SI1255754T1 (cg-RX-API-DMAC7.html)
SK (1) SK287025B6 (cg-RX-API-DMAC7.html)
TW (1) TWI297687B (cg-RX-API-DMAC7.html)
WO (1) WO2001057035A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200205162B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200088328A (ko) * 2017-11-16 2020-07-22 페르시카 파마슈티컬스 리미티드 리네졸리드 제제

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100490643B1 (ko) * 2002-10-29 2005-05-19 한국과학기술연구원 새로운 메틸리덴 피페리딘일 옥사졸리딘온 유도체 및이들의 제조방법
ES2803516T3 (es) 2003-10-16 2021-01-27 Symed Labs Ltd Una forma cristalina de linezolid
ES2294494T3 (es) 2004-04-19 2008-04-01 Symed Labs Limited Un nuevo procedimiento para la preparacion de linezolid y compuestos relacionados.
WO2006110155A1 (en) * 2004-06-29 2006-10-19 Teva Pharmaceutical Industries Ltd Solid forms of linezolid and processes for preparation thereof
CA2572054A1 (en) * 2004-06-29 2006-01-12 Teva Pharmaceutical Industries Ltd. Crystalline form iv of linezolid
CA2602073A1 (en) * 2005-02-24 2006-08-31 Teva Pharmaceutical Industries Ltd. Processes for the preparation of linezolid intermediate
JP2008514734A (ja) * 2005-06-22 2008-05-08 テバ ファーマシューティカル インダストリーズ リミティド マレイン酸テガセロドの多型体
PL1749517T3 (pl) * 2005-07-20 2008-12-31 Teva Pharma Trwała farmaceutyczna kompozycja zawierająca linezolid
WO2007102082A1 (en) * 2006-03-09 2007-09-13 Glenmark Pharmaceuticals Limited High oxazolidinone content solid dosage forms
US20080139563A1 (en) * 2006-10-23 2008-06-12 Concert Pharmaceuticals Inc. Oxazolidinone derivatives and methods of use
WO2011050826A1 (en) 2009-10-28 2011-05-05 Synthon B.V. Process for making crystalline form a of linezolid
JP5865898B2 (ja) 2010-04-30 2016-02-17 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ リネゾリドを調製するためのプロセス
EP2690100A1 (en) 2010-08-11 2014-01-29 Synhton B.V. Process for making linezolid
EP2603505A1 (en) 2010-08-11 2013-06-19 Synthon BV Process for making linezolid
CN103402990A (zh) * 2011-02-24 2013-11-20 李药业有限公司 无水利奈唑胺晶型-ii
WO2012119653A1 (en) 2011-03-09 2012-09-13 Synthon Bv Process for making crystalline form a of linezolid
CN102731341A (zh) * 2011-04-13 2012-10-17 上海医药工业研究院 用于制备利奈唑胺的中间体及其制备方法
CN102766106A (zh) * 2011-05-03 2012-11-07 江苏豪森医药集团有限公司 利奈唑胺的新晶型及其制备方法
CN102399200B (zh) * 2011-12-14 2013-12-04 浙江新东港药业股份有限公司 一种利用悬浮结晶法制备利奈唑胺晶型ⅰ的方法
IN2014DN06213A (cg-RX-API-DMAC7.html) 2012-01-24 2015-10-23 Jubilant Life Sciences Ltd
WO2013120496A1 (en) 2012-02-14 2013-08-22 Pharmathen S.A. Process for the preparation of linezolid in crystalline form and salts thereof
CN102643245A (zh) * 2012-04-10 2012-08-22 杭州华东医药集团生物工程研究所有限公司 一种利奈唑胺晶型及其制备方法
WO2014071990A1 (en) 2012-11-09 2014-05-15 Synthon Bv Process for making linezolid
KR102615354B1 (ko) 2016-11-16 2023-12-21 페르시카 파마슈티컬스 리미티드 요통을 위한 항생제 제형

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688792A (en) * 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK283420B6 (sk) * 1992-05-08 2003-07-01 Pharmacia & Upjohn Company Antimikrobiálne oxazolidinóny obsahujúce substituované diazínové skupiny
MY115155A (en) * 1993-09-09 2003-04-30 Upjohn Co Substituted oxazine and thiazine oxazolidinone antimicrobials.
SG85683A1 (en) * 1996-04-11 2002-01-15 Upjohn Co Process to prepare oxazolidinones
EE04370B1 (et) * 1997-11-07 2004-10-15 Pharmacia & Upjohn Company Oksasolidinoonide valmistamismeetod, meetodis kasutatavad vaheühendid ja nende valmistamine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688792A (en) * 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200088328A (ko) * 2017-11-16 2020-07-22 페르시카 파마슈티컬스 리미티드 리네졸리드 제제
KR102787942B1 (ko) 2017-11-16 2025-03-31 페르시카 파마슈티컬스 리미티드 리네졸리드 제제

Also Published As

Publication number Publication date
AU3275501A (en) 2001-08-14
CZ20022635A3 (cs) 2002-10-16
PT1255754E (pt) 2005-11-30
DE60111497D1 (de) 2005-07-21
KR20070087178A (ko) 2007-08-27
NO20023654D0 (no) 2002-08-01
EA200200819A1 (ru) 2003-02-27
CA2395603A1 (en) 2001-08-09
EE05197B1 (et) 2009-08-17
ES2242728T3 (es) 2005-11-16
ATE297920T1 (de) 2005-07-15
PL356433A1 (en) 2004-06-28
EP1255754A1 (en) 2002-11-13
SK287025B6 (sk) 2009-10-07
KR100781815B1 (ko) 2007-12-03
AR027261A1 (es) 2003-03-19
KR20080044358A (ko) 2008-05-20
NO20065836L (no) 2002-08-01
CN1394207A (zh) 2003-01-29
SK9942002A3 (en) 2002-11-06
IL151010A0 (en) 2003-02-12
CA2395603C (en) 2010-03-23
NO20023654L (no) 2002-08-01
CN1221547C (zh) 2005-10-05
HK1051196A1 (en) 2003-07-25
AU782138B2 (en) 2005-07-07
TWI297687B (en) 2008-06-11
SI1255754T1 (sl) 2005-12-31
EE200200420A (et) 2003-12-15
KR20020072300A (ko) 2002-09-14
EP1255754B1 (en) 2005-06-15
ZA200205162B (en) 2003-09-29
MXPA02007471A (es) 2002-12-13
EA004434B1 (ru) 2004-04-29
CZ302292B6 (cs) 2011-02-09
CO5261555A1 (es) 2003-03-31
MY122829A (en) 2006-05-31
DE60111497T2 (de) 2006-05-18
NO323459B1 (no) 2007-05-14
NZ520541A (en) 2004-02-27
HUP0301076A3 (en) 2004-06-28
BR0107667A (pt) 2002-10-08
PE20011086A1 (es) 2001-10-04
JP5235256B2 (ja) 2013-07-10
HUP0301076A2 (hu) 2003-08-28
DK1255754T3 (da) 2005-08-22
WO2001057035A1 (en) 2001-08-09
JP2003522175A (ja) 2003-07-22

Similar Documents

Publication Publication Date Title
KR100864745B1 (ko) 리네졸리드 결정 형태 ⅱ
US6559305B1 (en) Linezolid—crystal form II
SK2802001A3 (en) Crystalline forms of eto2c-ch2-(r)cgl-aze-pab-oh
AU1641592A (en) Crystalline tiagabine hydrochloride monohydrate, its preparation and use
EP1908756A1 (en) Processes for preparation of crystalline mycophenolate sodium
US5015646A (en) Pharmaceutically useful polymorphic modification of buspirone
JP2702519B2 (ja) 多形結晶形態の転換法
JPH06192228A (ja) 結晶性（ｒ）−（−）−２−シクロヘプチル−ｎ−メチルスルフオニル−［４−（２−キノリニルメトキシ）−フエニル］−アセトアミド
EP1384708A1 (en) Process for the manufacture of form I of nolomirole hydrochloride
HK1051196B (en) Linezolid-crystal form ii
JP2004536868A (ja) 不整脈治療用のピリダジノン誘導体の多形体塩
WO2022023291A1 (en) Method for the purification of vilanterol trifenatate
EP3372592A1 (en) Solid forms of lesinurad amine salts
FR2554109A1 (fr) Nouveaux derives de la 1,4-dihydropyridine, leur preparation et leur utilisation en therapeutique comme medicaments
HUP0900062A2 (en) Novel polymorphs and amorph forms of desvenlafaxine fumarate

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

A107 Divisional application of patent
AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

St.27 status event code: A-3-4-F10-F13-rex-PB0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U12-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

Not in force date: 20111016

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

St.27 status event code: A-4-4-U10-U13-oth-PC1903

PC1903 Unpaid annual fee

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20111016

St.27 status event code: N-4-6-H10-H13-oth-PC1903

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000